Alaska Marijuana Control Board to Vote on Eliminating THC Purchase Limits

Proposed Regulatory Changes

The board will consider three distinct rule amendments that collectively roll back consumer-protection and advertising guardrails established under Alaska's original cannabis framework. The proposals were advanced to the September 24, 2026 meeting following industry petitions and staff review conducted over the summer.

The first proposal addresses Alaska Administrative Code Title 3, Chapter 306.355, which currently imposes a one-ounce flower equivalent daily purchase limit on adult consumers. Eliminating this cap would align Alaska with states like Colorado and Oregon, which don't impose transaction-level THC ceilings. The existing statute functions as a per-visit restriction rather than a daily aggregate across all retailers, complicating enforcement and creating compliance ambiguity for multi-location operators.

The second item targets 3 AAC 306.770, the advertising standards section that mandates health-warning language on all cannabis advertisements. Current regulations require warnings about impaired driving, addiction risk, and prohibitions on youth access. Industry petitioners argued the warnings impose disproportionate costs on small retailers and duplicate federal labeling requirements already enforced at point of sale.

Marketing Restriction Revisions

A third proposal would amend 3 AAC 306.770(c) to permit cannabis retailers to advertise strain-specific effects, flavor profiles, and cannabinoid ratios—claims currently classified as therapeutic and therefore prohibited under Alaska's marketing code. The existing rule was drafted to prevent unlicensed medical claims. Operators contend the prohibition extends too far and prevents factual product differentiation.

According to the Marijuana Control Board's published agenda, the meeting will take place at 9:00 a.m. Alaska Time in Anchorage. Public comment periods are scheduled for each agenda item. The board has authority under AS 17.38.121 to adopt, amend, or repeal regulations governing the cannabis industry without legislative approval, though substantive changes typically undergo a 30-day public notice period before final adoption.

Alaska legalized adult-use cannabis in 2014 via Ballot Measure 2, with the first retail licenses issued in 2016. The state collected $28.7 million in cannabis excise tax revenue in fiscal year 2025, according to the Alaska Department of Revenue. The current excise tax is structured as a $50-per-ounce cultivation tax rather than a percentage-of-sale retail tax, insulating state revenue from the proposed purchase-limit change.

Industry and Regulatory Context

Alaska's cannabis market remains one of the smallest among adult-use states, with approximately 140 active retail licenses statewide as of August 2026. The state's remote geography and small population—roughly 733,000 residents—create unique compliance costs. Operators say these justify regulatory streamlining. For full background on this story, see the CannIntel topic hub on Alaska Cannabis Regulations.

The Marijuana Control Board is a five-member body appointed by the governor and confirmed by the legislature. Current members include representatives from public health, public safety, rural communities, and the cannabis industry itself. Board meetings are open to the public. They're streamed online via the state's Alaska Online Public Notice System.

If adopted, the rule changes would take effect 30 days after final publication in the Alaska Administrative Register, likely in late October 2026. Operators wouldn't be required to immediately adjust advertising or point-of-sale systems, but the removal of purchase limits would allow same-day bulk transactions that currently require multiple store visits or coordination across license holders.

Next signal: final board vote results and any amendments adopted during Tuesday's session. We'll be monitoring the public comment record and any dissenting opinions filed by board members, particularly on the advertising-warning question, which has drawn opposition from public-health advocates in prior rulemaking cycles.